Schedule of Segment Reporting Significant Expense (Details) - Titan Pharmaceuticals Inc [Member] - USD ($) $ in Thousands |
12 Months Ended | |
|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Salaries and employee compensation and benefits | $ 60 | $ 1,505 |
| Professional fees | 1,333 | 1,628 |
| Insurance expenses | 453 | 485 |
| Board of directors’ fees | 128 | 457 |
| Total | $ 1,974 | $ 4,075 |
| X | ||||||||||
- Definition Expenses from business segment reporting. No definition available.
|
| X | ||||||||||
- Definition The expense incurred by an insurance company to persons or entities for generating or placing insurance or investment contracts with the company, usually determined as a percentage of policy or contract premiums. Excludes advances or draws to be applied against commissions earned. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for service provided by entity's director. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|